Of note, FOLFIRI response was not altered by p130Cas knockdown in MCF7 breast cancer cells, indicating distinct mechanisms modulating p130Cas-mediated therapy response in CRC and breast cancer. This evidence concerns the gene BCAR1 and breast cancer.